US Patent

US8865730 — Polymorphic forms of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one

Method of Use · Assigned to Gilead Calistoga LLC · Expires 2033-03-05 · 7y remaining

Vulnerability score 67/100 Moderate — design-around opportunities exist

What this patent protects

This patent discloses polymorphs of a specific compound, methods for preparing them, and methods for their use.

USPTO Abstract

Polymorphs of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one, compositions thereof, methods for their preparation, and methods for their use are disclosed.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-1615 —
U-1615 —

Patent Metadata

Patent number
US8865730
Jurisdiction
US
Classification
Method of Use
Expires
2033-03-05
Drug substance claim
Yes
Drug product claim
Yes
Assignee
Gilead Calistoga LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.